

# Lan-Ping Xu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2522589/lan-ping-xu-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

347  
papers

6,079  
citations

36  
h-index

67  
g-index

412  
ext. papers

7,988  
ext. citations

4.8  
avg. IF

5.49  
L-index

#	Paper	IF	Citations
347	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. <i>Blood</i> , <b>2006</b> , 107, 3065-73	2.2	412
346	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. <i>Blood</i> , <b>2015</b> , 125, 3956-62	2.2	268
345	Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 257-65	4.7	235
344	Who is the best donor for a related HLA haplotype-mismatched transplant?. <i>Blood</i> , <b>2014</b> , 124, 843-50	2.2	215
343	Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2012</b> , 119, 3256-62	2.2	206
342	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , <b>2013</b> , 121, 4056-62	2.2	206
341	Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. <i>Cancer</i> , <b>2013</b> , 119, 978-85	6.4	182
340	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 33	22.4	129
339	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. <i>Haematologica</i> , <b>2007</b> , 92, 414-7	6.6	127
338	Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 821-30	4.7	115
337	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 84	22.4	106
336	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3467-76	12.9	96
335	Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 25	22.4	92
334	Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2012</b> , 91, 183-92	3	84
333	Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1465-73	4.7	80
332	In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. <i>Blood</i> , <b>2014</b> , 124, 1880-6	2.2	79
331	Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 265-274	4.5	75

330	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 134	22.4	74
329	Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 469-77	4.7	74
328	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. <i>Cancer Letters</i> , <b>2018</b> , 438, 63-75	9.9	73
327	Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. <i>Journal of Clinical Immunology</i> , <b>2012</b> , 32, 268-80	5.7	70
326	Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. <i>Blood</i> , <b>2011</b> , 117, 3032-40	2.2	62
325	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. <i>Annals of Hematology</i> , <b>2013</b> , 92, 1111-9	3	61
324	Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 598-605	4.5	59
323	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1855-63	2.2	57
322	Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study. <i>Journal of Clinical Immunology</i> , <b>2008</b> , 28, 390-7	5.7	56
321	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. <i>Blood</i> , <b>2016</b> , 128, 2988-2999	2.2	52
320	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 945-956	7	49
319	The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1699-705	3	47
318	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1311-1319	4.7	43
317	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 87	22.4	41
316	Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 550-5	7.1	41
315	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , <b>2014</b> , 38, 1435-40	2.7	39
314	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. <i>Stem Cells Translational Medicine</i> , <b>2016</b> , 5, 1631-1643	6.9	38
313	Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1190-7	4.7	37

312	Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2185-2191	4.7	36
311	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. <i>Cancer</i> , <b>2017</b> , 123, 2881-2892	6.4	35
310	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 2106-15	7.5	35
309	Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. <i>European Journal of Haematology</i> , <b>2013</b> , 91, 304-14	3.8	35
308	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. <i>Oncotarget</i> , <b>2016</b> , 7, 30892-906	3.3	35
307	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 88	22.4	33
306	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1697-707	7.5	33
305	Prolonged thrombocytopenia following allogeneic hematopoietic stem cell transplantation and its association with a reduction in ploidy and an immaturation of megakaryocytes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 274-80	4.7	33
304	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 44	22.4	32
303	The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. <i>Clinical Transplantation</i> , <b>2012</b> , 26, 284-91	3.8	31
302	Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation. <i>European Journal of Immunology</i> , <b>2015</b> , 45, 2396-408	6.1	30
301	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: IFN- $\gamma$ is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1303-1310	3.8	30
300	IFN- $\gamma$ is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1303-1310	4.7	29
299	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2017</b> , 96, 829-838	3	28
298	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. <i>Stem Cells and Development</i> , <b>2017</b> , 26, 1648-1661	4.4	27
297	Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1314-21	4.7	27
296	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 116	22.4	27
295	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 741-750	4.7	27

294	Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1110-6	4.7	26
293	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. <i>Blood</i> , <b>2018</b> , 131, 1219-1233	2.2	26
292	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. <i>BMC Cancer</i> , <b>2016</b> , 16, 269	4.8	26
291	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1310-1318	4.4	24
290	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , <b>2017</b> , 4, e487-e496	14.6	24
289	Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 283-90	4.7	24
288	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. <i>Blood Advances</i> , <b>2019</b> , 3, 1303-1317	7.8	24
287	An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 679-692	4.5	24
286	Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1611-1620	4.7	23
285	Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 57	8.5	22
284	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF- $\kappa$ B/SMAD pathway in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 395-411	4.5	22
283	Early myeloid-derived suppressor cells (HLA-DR/CD33CD16) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 103-111	22.4	21
282	G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1419-1433	4.4	19
281	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3116-23	1.9	19
280	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 27	22.4	19
279	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 145	22.4	19
278	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. <i>Oncol Immunology</i> , <b>2017</b> , 6, e1284721	7.2	18
277	Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 929-36	4.7	18

276	The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 1100-6	3	18
275	Reference data and predictive diagnostic models for calcaneus bone mineral density measured with single-energy X-ray absorptiometry in 7428 Chinese. <i>Osteoporosis International</i> , <b>2001</b> , 12, 755-62	5.3	18
274	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1637-43	3	18
273	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , <b>2019</b> , 3, 4312-4325	7.8	18
272	Viral encephalitis after haplo-identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 450-458	3.8	17
271	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 906-912	4.7	17
270	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. <i>Oncolimmunology</i> , <b>2017</b> , 6, e1356152	7.2	17
269	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1319-1326	4.4	17
268	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , <b>2018</b> , 97, 967-975	3	17
267	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. <i>Journal of Clinical Virology</i> , <b>2016</b> , 75, 10-5	14.5	17
266	Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 716-21	4.7	17
265	Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. <i>Annals of Hematology</i> , <b>2015</b> , 94, 117-28	3	16
264	N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 931-942	7.1	16
263	Inverse correlation of V $\alpha$ T-cell recovery with EBV reactivation after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 276-285	4.5	16
262	First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13179	3.8	16
261	Monitoring of post-transplant CFBF-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 448-451	4.5	16
260	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1139274	7.2	16
259	Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1981-1989	4.7	16

258	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1429-1437	11.6	16
257	Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 927-936	7.1	16
256	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. <i>OncImmunity</i> , <b>2016</b> , 5, e1250992	7.2	15
255	High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. <i>Annals of Hematology</i> , <b>2009</b> , 88, 1015-24	3	15
254	N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 863-878	4.5	14
253	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Clinical Immunology</i> , <b>2018</b> , 190, 32-40	9	14
252	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 391	8.5	14
251	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. <i>Transfusion</i> , <b>2015</b> , 55, 2023-31	2.9	14
250	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte-colony-stimulating factor-mobilized marrow harvests and peripheral blood harvests. <i>Transfusion</i> , <b>2015</b> , 55, 2874-81	2.9	14
249	Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1176-82	4.7	14
248	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. <i>Science China Life Sciences</i> , <b>2019</b> , 62, 691-697	8.5	14
247	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). <i>Science China Life Sciences</i> , <b>2020</b> , 63, 571-584	8.5	14
246	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, S162-S173	11.6	14
245	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2143-2150	4.7	13
244	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1737-1748	12.9	13
243	Interferon-β salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , <b>2019</b> , 13, 238-249	12	13
242	All- retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop. <i>Haematologica</i> , <b>2019</b> , 104, 1661-1675	6.6	12
241	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1547-1554	3	12

240	Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. <i>Clinical Transplantation</i> , <b>2015</b> , 29, 594-605	3.8	12
239	Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. <i>Oncotarget</i> , <b>2017</b> , 8, 35984-36000	3.3	12
238	M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 234	2.1	12
237	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1080-1086	4.7	12
236	Interferon- $\beta$ s Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. <i>Oncologist</i> , <b>2018</b> , 23, 1349-1357	5.7	12
235	Interferon $\beta$ the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 2583-7	2.9	12
234	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 3602-9	2.9	12
233	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1147-1160	4.4	11
232	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1936-1943	4.7	11
231	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1233-40	3	11
230	Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 870-886	4.5	11
229	Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E659-E661	7.1	11
228	Haploidentical stem cell transplantation in patients aged 50 yr and older with leukemia: similar outcomes compared to younger adults. <i>Clinical Transplantation</i> , <b>2015</b> , 29, 523-30	3.8	11
227	Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. <i>Clinical Transplantation</i> , <b>2013</b> , 27, 844-51	3.8	11
226	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 757-767	4.5	11
225	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 87	22.4	10
224	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Chinese Journal of Cancer</i> , <b>2016</b> , 35, 46		10
223	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 76	7	10

222	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1135-1143	1.9	10
221	Infusion-related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft-versus-host disease. <i>Pediatric Transplantation</i> , <b>2015</b> , 19, 918-24	1.8	10
220	Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 649-56	4.7	10
219	Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 766-781	4.5	9
218	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. <i>EBioMedicine</i> , <b>2020</b> , 53, 102677	8.8	9
217	Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. <i>Clinical Transplantation</i> , <b>2020</b> , 34, e13810	3.8	9
216	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting V $\alpha$ T cells activities after hematopoietic transplantation for blood malignancies <b>2020</b> , 8,		9
215	Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. <i>Journal of Immunology Research</i> , <b>2017</b> , 2017, 1043836	4.5	9
214	Lower incidence of acute GVHD is associated with the rapid recovery of CD4CD25CD45RA regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. <i>Oncot Immunology</i> , <b>2016</b> , 5, e1242546	7.2	9
213	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 770-773	4.4	9
212	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 351-357	4.7	9
211	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. <i>Clinical Transplantation</i> , <b>2016</b> , 30, 994-1001	3.8	9
210	GII.4 Sydney_2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo. <i>Journal of Medical Virology</i> , <b>2016</b> , 88, 224-33	19.7	9
209	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 320	5.3	9
208	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1877-1883	3	8
207	Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1326-1336	4.4	8
206	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. <i>Annals of Hematology</i> , <b>2018</b> , 97, 485-495	3	8
205	Homeostatic T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of T Cell Subsets after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 252-259	4.7	8

204	Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. <i>Science China Life Sciences</i> , <b>2018</b> , 61, 569-577	8.5	8
203	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. <i>Journal of Infection</i> , <b>2016</b> , 73, 261-70	18.9	8
202	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. <i>Clinical Transplantation</i> , <b>2016</b> , 30, 170-8	3.8	8
201	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2235-2242	4.7	8
200	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. <i>Cancer Letters</i> , <b>2019</b> , 442, 193-201	9.9	8
199	Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. <i>European Journal of Haematology</i> , <b>2018</b> , 100, 171-181	3.8	8
198	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , <b>2019</b> , 13, 354-364	12	7
197	Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. <i>BMC Cancer</i> , <b>2020</b> , 20, 553	4.8	7
196	Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 533-544	4.5	7
195	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 483-486	4.4	7
194	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 600-608	4.4	7
193	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , <b>2017</b> , 95, 20-25	14.5	7
192	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , <b>2020</b> , 22, 755-761	4.8	7
191	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. <i>Leukemia</i> , <b>2021</b> , 35, 3092-3100	10.7	7
190	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 517-26	3.8	7
189	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 788-796	4.5	7
188	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. <i>Annals of Hematology</i> , <b>2021</b> , 100, 169-180	3	7
187	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 620891	8.4	7

186	Dendritic Cells Are Critical for the Activation and Expansion of V $\alpha$ T Cells After Allogeneic Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2528	8.4	7
185	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2940-2947	4.4	7
184	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1158-1164	4.7	6
183	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 52	22.4	6
182	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2035-2042	4.4	6
181	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. <i>Science China Life Sciences</i> , <b>2020</b> , 63, 1552-1564	8.5	6
180	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1203-1209	4.7	6
179	Diminished expression of $\alpha$ -GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. <i>Annals of Hematology</i> , <b>2018</b> , 97, 641-654	6.3	6
178	IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1399-1406	3	6
177	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1209-1217	3	6
176	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. <i>Leukemia Research</i> , <b>2016</b> , 47, 8-15	2.7	6
175	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2133-9	1.9	6
174	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. <i>Leukemia Research</i> , <b>2017</b> , 59, 136-141	2.7	6
173	CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 105397-105406	3.3	6
172	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. <i>Platelets</i> , <b>2019</b> , 30, 994-1000	3.6	6
171	The loss or absence of minimal residual disease of . <i>British Journal of Haematology</i> , <b>2021</b> , 192, 265-271	4.5	6
170	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic HSCT patients. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13146	3.8	6
169	Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease. <i>Chinese Medical Journal</i> , <b>2007</b> , 120, 1666-71	2.9	6

168	Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. <i>Frontiers of Medicine</i> , <b>2015</b> , 9, 304-11	12	5
167	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 163-168	4.7	5
166	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K-AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. <i>Thrombosis Research</i> , <b>2016</b> , 139, 1-9	8.2	5
165	Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia. <i>Pediatric Transplantation</i> , <b>2016</b> , 20, 572-80	1.8	5
164	Dysregulated megakaryocyte distribution associated with nestin mesenchymal stem cells in immune thrombocytopenia. <i>Blood Advances</i> , <b>2019</b> , 3, 1416-1428	7.8	5
163	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1198-1207	4.4	5
162	Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen. <i>Science China Life Sciences</i> , <b>2020</b> , 63, 940-942	8.5	5
161	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Chinese Medical Journal</i> , <b>2018</b> , 131, 2808-2816	2.9	5
160	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e688-e699	14.6	5
159	Negative association of donor age with CD34+ cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 3597-601	2.9	5
158	The prognostic significance of WilmsTumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2551-2559	3	4
157	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1462-1470	4.4	4
156	Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1694-1700	4.4	4
155	S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 836-851	4.5	4
154	Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). <i>British Journal of Haematology</i> , <b>2020</b> , 190, 274-283	4.5	4
153	Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , <b>2020</b> , 91, 106333	2.7	4
152	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 507-510	4.4	4
151	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. <i>Human Immunology</i> , <b>2018</b> , 79, 672-677	2.3	4

150	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. <i>Science China Life Sciences</i> , <b>2019</b> , 62, 104-111	8.5	4
149	Modification of donor lymphocyte infusion: how to improve the outcome?. <i>Science China Life Sciences</i> , <b>2019</b> , 62, 1253-1256	8.5	4
148	Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 153-161	4.5	4
147	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1171-1178	4.7	4
146	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2659-2670	3	4
145	Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma. <i>Chinese Medical Journal</i> , <b>2019</b> , 132, 1765-1772	2.9	4
144	Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group. <i>Chinese Medical Journal</i> , <b>2011</b> , 124, 2548-55	2.9	4
143	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1733-1742	3	3
142	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2087-2097	4.4	3
141	Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. <i>Science China Life Sciences</i> , <b>2020</b> , 63, 1744-1754	8.5	3
140	Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1068-1075	4.4	3
139	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 67-78	4.5	3
138	Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. <i>Platelets</i> , <b>2016</b> , 27, 223-9	3.6	3
137	Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 20-20	2.2	3
136	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. <i>Blood</i> , <b>2013</b> , 122, 3322-3322	2.2	3
135	Preemptive interferon- $\gamma$ treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. <i>Scientific Reports</i> , <b>2020</b> , 10, 20148	4.9	3
134	The Prognostic Significance of Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 632532	5.3	3
133	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 67	7	3

132	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. <i>Thrombosis Research</i> , <b>2016</b> , 144, 6-11	8.2	3
131	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. <i>Blood Advances</i> , <b>2019</b> , 3, 3406-3418	7.8	3
130	Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1287-1294	4.4	3
129	Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 912-920	4.7	3
128	Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. <i>Cancer Communications</i> , <b>2021</b> , 41, 333-344	9.4	3
127	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia: Effects of CD34 and CD14 Cell Doses. <i>Chinese Medical Journal</i> , <b>2018</b> , 131, 2185-2192	2.9	3
126	Reduced $\alpha$ -GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Science China Life Sciences</i> , <b>2019</b> , 62, 921-929	8.5	2
125	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. <i>Blood Advances</i> , <b>2020</b> , 4, 5846-5857	7.8	2
124	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1833-1843	3	2
123	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1452-1458	4.7	2
122	Late-onset Epstein-Barr virus-related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of T and B lymphocytes. <i>Clinical Transplantation</i> , <b>2015</b> , 29, 904-10	3.8	2
121	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft--host disease after haploidentical allogeneic hematopoietic stem cell transplantation.. <i>Therapeutic Advances in Hematology</i> , <b>2022</b> , 13, 20406207211072838	5.7	2
120	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , <b>2021</b> ,	2.2	2
119	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1643-1653 <sup>3</sup>		2
118	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Medicine (United States)</i> , <b>2020</b> , 99, e23569	1.8	2
117	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 188-195	5.1	2
116	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. <i>Pediatric Transplantation</i> , <b>2020</b> , 24, e13864	1.8	2
115	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1655-1662	4.7	2

114	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 631625	5.3	2
113	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 561-570	7.1	2
112	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2097-2107	4.4	2
111	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 604085	4.9	2
110	T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 687961	8.4	2
109	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 2219-25	2.6	2
108	Factors affecting the CD34 cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. <i>Transfusion and Apheresis Science</i> , <b>2016</b> , 55, 311-317	2.4	2
107	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13544	2.7	2
106	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2021</b> , 100, 505-516	3	2
105	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 639502	5.3	2
104	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , <b>2021</b> ,	10.7	2
103	Improved function and balance in T cell modulation by endothelial cells in young people. <i>Clinical and Experimental Immunology</i> , <b>2021</b> , 206, 196-207	6.2	2
102	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. <i>Annals of Hematology</i> , <b>2021</b> , 100, 555-562	3	2
101	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression.. <i>Journal of Immunology</i> , <b>2021</b> ,	5.3	2
100	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.. <i>BMC Medicine</i> , <b>2022</b> , 20, 140	11.4	2
99	Association between C-reactive protein levels in the first 1-3 days post-transplant and allogeneic immune reactions. <i>Biomarkers in Medicine</i> , <b>2017</b> , 11, 117-124	2.3	1
98	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1629-1636	4.7	1
97	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. <i>Frontiers in Medicine</i> , <b>2019</b> , 13, 492-503	12	1

96	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1210-1217	4.7	1
95	CD8CD161 T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1652-1654	4.4	1
94	Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graft-vs-host disease for young donors. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 9204-9216	5.6	1
93	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. <i>Science China Life Sciences</i> , <b>2020</b> , 63, 1261-1264	8.5	1
92	A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2649-2657	3	1
91	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. <i>Transplant Immunology</i> , <b>2018</b> , 48, 55-59	1.7	1
90	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. <i>Science China Life Sciences</i> , <b>2018</b> , 61, 924-933	8.5	1
89	Preemptive Interferon- $\gamma$ Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 757002	8.4	1
88	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.. <i>BMC Cancer</i> , <b>2022</b> , 22, 11	4.8	1
87	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 773394	5.3	1
86	CD4 + CD25 - CD69 + t Cells Is a Novel Subset of Regulatory T Cells Involved In the Prevention of Acute Graft-Versus-Host Disease In Human. <i>Blood</i> , <b>2010</b> , 116, 1250-1250	2.2	1
85	Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study. <i>Blood</i> , <b>2014</b> , 124, 1231-1231	2.2	1
84	Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors. <i>Blood</i> , <b>2015</b> , 126, 62-62	2.2	1
83	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. <i>Blood</i> , <b>2016</b> , 128, 2308-2308	2.2	1
82	Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia. <i>Blood</i> , <b>2016</b> , 128, 364-364	2.2	1
81	Endothelial Cell Dysfunction Is Involved in the Progression of Myelodysplastic Syndromes. <i>Blood</i> , <b>2021</b> , 138, 3668-3668	2.2	1
80	Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation. <i>Clinical Drug Investigation</i> , <b>2010</b> , 1	3.2	1
79	A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. <i>Clinical Transplantation</i> , <b>2021</b> , e14514	3.8	1

78	Effects of Granulocyte Colony-Stimulating Factor on Proliferation and Apoptosis of B Cells in Bone Marrow of Healthy Donors. <i>Transplantation Proceedings</i> , <b>2020</b> , 52, 345-352	1.1	1
77	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1267-1281	3	1
76	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. <i>Clinical Transplantation</i> , <b>2021</b> , 35, e14160	3.8	1
75	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. <i>Annals of Hematology</i> , <b>2021</b> , 100, 799-808	3	1
74	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1203-1212	3	1
73	HCMV modulates c-Mpl/IEX-1 pathway-mediated megakaryo/thrombopoiesis via PDGFR $\alpha$ and $\beta$ receptors after allo-HSCT. <i>Journal of Cellular Physiology</i> , <b>2021</b> , 236, 6726-6741	7	1
72	WilmsTumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>BMC Cancer</i> , <b>2021</b> , 21, 292	4.8	1
71	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1866-1872	4.7	1
70	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic Mutations Based on a Multi-Gene Panel and Nomogram Model. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 706935	5.3	1
69	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Host Disease. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 749266	8.4	1
68	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. <i>Blood Advances</i> , <b>2021</b> ,	7.8	1
67	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1341-1351	4.4	1
66	Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Chinese Medical Journal</i> , <b>2013</b> , 126, 768-74	2.9	1
65	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study.. <i>Therapeutic Advances in Hematology</i> , <b>2022</b> , 13, 20406207221095226	5.7	1
64	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation.. <i>Experimental Hematology and Oncology</i> , <b>2022</b> , 11, 25	7.8	1
63	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Frontiers of Medicine</i> , <b>2019</b> , 13, 667-679	12	0
62	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. <i>Thrombosis Research</i> , <b>2020</b> , 194, 168-175	8.2	0
61	Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates. <i>Scientific Reports</i> , <b>2020</b> , 10, 2367	4.9	0

60	Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12880	3.8	○
59	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 731435	8.4	○
58	Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets. <i>Blood</i> , <b>2021</b> , 138, 517-517	2.2	○
57	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020). <i>Blood</i> , <b>2021</b> , 138, 13-13	2.2	○
56	Prolonged Isolated Thrombocytopenia (PIT) Is Associated with Platelet Aggregation, Which Is Affected By Endothelial Progenitor Cells (EPCs) Following Allo-HSCT. <i>Blood</i> , <b>2014</b> , 124, 2513-2513	2.2	○
55	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 253.e1-253.e9		○
54	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. <i>Science China Life Sciences</i> , <b>2020</b> , 63, 138-147	8.5	○
53	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2723-2731	4.4	○
52	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 668.e1-668.e9		○
51	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , <b>2021</b> , 5, 4910-4921	7.8	○
50	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1407-1419	7.1	○
49	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2022</b> , 12, 862526	5.9	○
48	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 814334	8.4	○
47	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. <i>Blood</i> , <b>2020</b> , 136, 42-43	2.2	
46	M2 Macrophages, but Not M1 Macrophages, Support Megakaryopoiesis Via up-Regulating PI3K-AKT Pathway. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	
45	M1 and M2 Macrophages Play Different Roles in the Pathogenesis of Acute Graft-Versus-Host Disease Post-Allotransplant By Modulating Immune Microenvironment. <i>Blood</i> , <b>2020</b> , 136, 19-20	2.2	
44	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 4-5	2.2	
43	Different Subsets of Haematopoietic Cells and Immune Cells in Bone Marrow between Young and Old Donors. <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2	

42	All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP. <i>Blood</i> , <b>2021</b> , 138, 15-15	2.2
41	Machine-Learning Based Early Warning System for Prediction for Disseminated Intravascular Coagulation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Multicenter Study. <i>Blood</i> , <b>2021</b> , 138, 2113-2113	2.2
40	Detection of CSRP2 Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL. <i>Blood</i> , <b>2021</b> , 138, 3998-3998	2.2
39	Comparison of Transplant Donor and Third-Party Donor Derived CMV-Specific T Cells for CMV Infection after Allogenic Stem Cell Transplantation. <i>Blood</i> , <b>2021</b> , 138, 1701-1701	2.2
38	HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia.. <i>Blood</i> , <b>2006</b> , 108, 3154-3154	2.2
37	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course. <i>Blood</i> , <b>2018</b> , 132, 5734-5734	2.2
36	Positive Stool Cultures Could Predict the Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 5757-5757	2.2
35	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. <i>Blood</i> , <b>2018</b> , 132, 2813-2813	2.2
34	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. <i>Blood</i> , <b>2018</b> , 132, 360-360	2.2
33	The Lost or Absence of MRD. <i>Blood</i> , <b>2019</b> , 134, 2616-2616	2.2
32	Haploidentical Hematopoietic Stem Cell Transplantation May Improve Prognosis in Non-Infant Children with t(v;11q23)/MLL-Rearranged B-Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2049-2049 <sup>2,2</sup>	2.2
31	Autophagy in Endothelial Cells Regulates Their Hematopoiesis Supporting Ability. <i>Blood</i> , <b>2019</b> , 134, 4425-4425	2.2
30	PDGFR-Mediated Cytomegalovirus Infection of Megakaryocytes Induces Thrombocytopenia Via Demethylation of AML1 and IEX-1 in the TPO/c-Mpl Signaling Pathway Following Allo-HSCT. <i>Blood</i> , <b>2014</b> , 124, 3937-3937	2.2
29	Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study. <i>Blood</i> , <b>2014</b> , 124, 3770-3770	2.2
28	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. <i>Blood</i> , <b>2014</b> , 124, 40-40	2.2
27	Desialylation Induces Apoptosis and Phagocytosis of Platelets in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 432-432 <sup>2,2</sup>	2.2
26	The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2016</b> , 128, 5800-5800	2.2
25	Haploidentical Stem Cell Transplantation for Rare Pediatric Diseases at Peking University People's Hospital. <i>Blood</i> , <b>2016</b> , 128, 5848-5848	2.2

- 24 Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 4602-4602<sup>2,3</sup>
- 23 Desialylation of Megakaryocytes Diminishes Platelet Production By Disrupting Megakaryocyte Adhesion, Migration and Proplatelet Formation in Chronic Immune Thrombocytopenia. *Blood*, **2016**, 128, 165-165 2.2
- 22 Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. *Blood*, **2016**, 128, 3323-3323 2.2
- 21 ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. *Blood*, **2016**, 128, 2902-2902 2.2
- 20 Crucial Role of Complement Activation and IL-1 $\beta$  in Bone Marrow Niche of Immune Thrombocytopenia. *Blood*, **2016**, 128, 166-166 2.2
- 19 Optimal Dose of Antithymocyte Globulin in Conditioning Regimens for Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: Long-Term Outcomes of a Prospective Randomised Trial. *Blood*, **2016**, 128, 3433-3433 2.2
- 18 Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation. *Blood*, **2016**, 128, 5794-5794 2.2
- 17 Dysfunction of Bone Marrow Endothelial Progenitor Cells from Subjects with Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Can be Improved By Atorvastatin. *Blood*, **2016**, 128, 3386-3386 2.2
- 16 Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies.. *Blood*, **2009**, 114, 1197-1197 2.2
- 15 Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. *Blood*, **2010**, 116, 2347-2347<sup>2,3</sup>
- 14 Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. *Blood*, **2010**, 116, 2312-2312 2.2
- 13 Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Association with Reduced Ploidy and Immaturations of Megakaryocytes. *Blood*, **2010**, 116, 4695-4695 2.2
- 12 IL-17-Producing T Cells Contribute to Mediate Acute-graft-Versus-Disease In Patients Undergoing Unmanipulated Blood and Marrow Transplantation. *Blood*, **2010**, 116, 2310-2310 2.2
- 11 Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. *Blood*, **2011**, 118, 4161-4161 2.2
- 10 Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2011**, 118, 659-659 2.2
- 9 A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. *Blood*, **2012**, 120, 4512-4512 2.2
- 8 Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1346-1346 2.2
- 7 Lacking Of Missing Killer-Immunoglobulin-Like Receptor Ligand In Recipients Can Predict Better Prognosis After HLA-Mismatched/Haploidentical Transplantation Without T Cells Depletion In Vitro In Chronic Myeloid Leukemia Patients. *Blood*, **2013**, 122, 2165-2165 2.2

6	The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , <b>2020</b> , 24, e13793	1.8
5	Comments on the article: Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantationP <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2022</b> , 47, 688-693	4.5
4	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. <i>Frontiers of Medicine</i> , <b>2021</b> , 15, 728-739	12
3	Successful second transplantation from haploidentical donor for graft failure following unrelated cord blood cell transplantation or mismatched related transplantation: 2 cases report. <i>Chinese Medical Journal</i> , <b>2006</b> , 119, 1489-93	2.9
2	Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 292	4
1	Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes.. <i>Journal of Translational Medicine</i> , <b>2022</b> , 20, 144	8.5